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ABSTRACT
Allogeneic HCT after myeloablative conditioning is an effective therapy for patients with hematologic malig-
nancies. In an attempt to extend this therapy to older patients or those with comorbidities, reduced intensity
or truly nonmyeloablative regimens have been developed over the past decade. The principle underlying
reduced intensity regimens is to provide some tumor kill with lessened regimen-related morbidity and
mortality and then rely on graft-versus-tumor (GVT) effects to eradicate remaining malignant cells, whereas
nonmyeloablative regimens rely primarily on GVT effects. In this article, 3 representative approaches are
described, demonstrating the clinical application for hematopoietic and nonhematopoietic malignancies.
Current challenges include controlling GVHD while allowing GVT to occur. In the future, clinical trials using
reduced intensity and nonmyeloablative conditioning will be compared with myeloablative conditioning in
selected malignancies to extend the application to standard-risk patients.
© 2007 American Society for Blood and Marrow Transplantation
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Allogeneic HCT was developed as a method to
escue patients from severe myelosuppression after
raditional myeloablative chemoradiotherapy was given.
CT permitted intensiﬁcation of the chemoradio-
herapy well beyond the marrow-toxic range to the
oint at which nonhematopoietic toxicities became
ose limiting. Although increasing doses of chemo-
herapy or radiation resulted in lower relapse rates,
he survival was not improved due to higher nonre-
apse mortality (NRM). In addition, the nonhemato-
oietic toxicities severely limited the application of
llografting to patients 50 or 60 yr of age and who
id not have signiﬁcant comorbidities. Because the
edian age of patients with most candidate diseases
anges from 65 to 70 yr, most patients are not con-
entional transplantation candidates.
There are many factors responsible for disease
ontrol after HCT including disease burden at time of
CT, conditioning intensity, and graft source and
omposition. Considerable data indicate that much of she therapeutic beneﬁt of allogeneic HCT is related to
raft-versus-tumor (GVT) effects mediated by the do-
or-derived immunocompetent cells. The most direct
vidence is the ability of DLIs to induce a remission in
atients who have relapsed after HCT. The second
ine of clinical evidence comes from the observation of
educed risk of relapse in patients with GVHD. Other
vidence includes increased risk of relapse in T cell-
epleted or syngeneic HCT and the failure to elim-
nate minimal residual disease after T cell-replete
CT. Different reduced intensity and nonmyeloabla-
ive conditioning regimens have been explored for
ematopoietic and nonhematopoietic malignancies.
he conditioning regimens typically include a purine
nalog, such as ﬂudarabine, an alkylating agent, or
ow-dose TBI. The principle underlying reduced
ntensity conditioning regimens is to provide tumor
ill using drugs with proven activities against the
argeted malignancies while waiting for GVT effects
o occur. The cytotoxic conditioning also serves to
uppress the host-versus-graft reactions. The second
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B. M. Sandmaier et al.88pproach of nonmyeloablative conditioning employs
n immunosuppressive regimen that is minimally my-
losuppressive. Postgrafting immunosuppression is
sed for the dual purposes of enhancing engraftment
nd controlling GVHD.
Over the past decade, many groups of investiga-
ors have explored variations of these less intensive
reparative regimens. In this article, 3 representative
pproaches are described, demonstrating the clinical
pplication for reduced intensity conditioning for he-
atopoietic and nonhematopoietic malignancies.
ONMYELOABLATIVE HCT USING LOW-DOSE
BI-BASED CONDITIONING REGIMENS
To extend the clinical use of allogeneic HCT to
lder patients and those with comorbidities, a truly
onmyeloablative HCT regimen was developed based
n studies in a preclinical canine model [1]. Stable
onor hematopoietic chimerism was achieved using
-Gy TBI followed by postgrafting immunosuppres-
ion with cyclosporine and mycophenolate mofetil
MMF). This regimen was translated to patients in a
ulti-institutional clinical trial in recipients of HLA-
dentical sibling HCT using G-CSF mobilized PBSCs
2]. The hematologic changes were milder than usu-
lly observed after myeloablative or reduced intensity
CT, with most patients having full donor chimer-
sm. Nonfatal graft rejections occurred in 20% of
atients, primarily those who had not received pre-
eding myelosuppressive chemotherapy, this was re-
uced to 3% with the addition of ﬂudarabine (90
g/m2) to the 2-Gy TBI [3]. The same ﬂudarabine
nd 2-Gy TBI regimen was used in recipients of 10/10
LA-antigen matched unrelated donor grafts with
se of extended MMF/cyclosporine immunosuppres-
ion [4]. Donor T cell chimerism and durable engraft-
ent were higher in recipients of PBSCs compared to
M recipients, leading to exclusive use of PBSCs in
ubsequent trials using this nonmyeloablative regi-
en. Based on MMF pharmacokinetic studies, a sub-
equent trial of thrice daily, rather than twice daily,
MF successively reduced the risk of graft rejection
n recipients of unrelated donor PBSC grafts [5].
dvantages of Reduced Intensity Conditioning
egimens
The most important beneﬁt of a reduced intensity
including nonmyeloablative) conditioning regimen
ncludes a reduction in morbidity and NRM, even in
lder patients and those with comorbidities. Only
7% of patients conditioned with the ﬂudarabine/TBI
egimen required hospitalization and the median du-
ation of stay was 8 d [2]. There was a signiﬁcant
eduction in the need for RBC (63% versus 96%; P 
001) and platelet (23% versus 100%; P  .0001) pransfusions in recipients of nonmyeloablative versus
yeloablative conditioning [6]. Durations of neutro-
enia and early bacteremia were also reduced in the
onmyeloablative recipients, although there was no
ifference in the incidence of fungal disease [7]. The
umulative incidence of idiopathic pneumonia syn-
rome was signiﬁcantly lower [8], and no case of
eno-occlusive disease was observed [9].
nfluence of Pretransplantation Comorbidities
n Outcome
With the advent of reduced intensity and nonmy-
loablative conditioning regimens, allogeneic HCT is
urrently being given to older and more heavily pre-
reated patients. In addition to the physiologic effects
f aging, much of the increased morbidity and mor-
ality is associated with pre-existing medical condi-
ions related or unrelated to previous therapy for the
nderlying malignancy. The Charlson Comorbidity
ndex (CCI) was used to evaluate outcomes in patients
ndergoing nonmyeloablative and myeloablative con-
itioning before HCT [10,11]. The CCI was useful in
redicting NRM and overall survival in recipients of
elated and unrelated donor grafts. The patients re-
eiving nonmyeloablative conditioning had higher
CI scores and were older, yet had signiﬁcantly lower
RM than did patients prepared with myeloablative
egimens. More recently, an HCT-speciﬁc comorbid-
ty index (HCT-CI) was developed that included co-
orbidities that were most relevant for HCT and was
ound to have a higher discriminative capacity [12].
he HCT-CI captured 62% of study patients with
cores 0 compared with 12% with the CCI. Cur-
ently, the HCT-CI is being validated at multiple
ransplantation centers and, in the future, may be
elpful in determining the most appropriate intensity
f conditioning regimen for any given patient.
himerism and Graft Composition
The kinetics of donor engraftment were analyzed
n patients with hematologic malignancies given re-
ated or unrelated donor grafts after 2-Gy TBI with or
ithout ﬂudarabine [13]. Although patients rapidly
eveloped high degrees of donor engraftment, most
emained mixed donor/host chimeras for up to 6 mo.
hose given preceding chemotherapy and patients
ith PBSC grafts had the highest degrees of donor
himerism. Low donor T cell and NK cell chimerism
evels on day 14 were associated with graft rejection,
hereas high T cell chimerism on day 28 was associ-
ted with aGVHD. Earlier establishment of donor
K cell chimerism was associated with better progres-
ion-free survival. Achievement of full donor chimer-
sm was associated with a decreased risk of progression
r relapse [14]. These data suggest that monitoring
eripheral blood subset chimerism might allow inter-
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Reduced Intensity Allogeneic Transplantation 89entions soon after HCT to prevent rejection or re-
apse.
The effect of graft composition on chimerism was
nvestigated in recipients of unrelated donor PBSC
rafts. Higher numbers of CD34 cells were associated
ith higher levels of complete donor T cell chimerism
t day 28 with a trend for less graft rejection [15].
igher numbers of CD34 cells in related donor re-
ipients had a beneﬁcial effect on survival [16]. There
ere no associations between any cell subsets (includ-
ng CD34) and aGVHD or cGVHD in the related or
nrelated donor recipients.
VHD and HCT Outcomes
In a retrospective analysis of patients 50-65 yr of
ge, the incidence of aGVHD was reduced in recipients
f nonmyeloablative versus myeloablative conditioning,
ut no difference was observed in the cumulative inci-
ence of cGVHD requiring therapy [17]. Nonmyeloa-
lative HCT was associated with a syndrome of late
nset aGVHD in some patients occurring beyond day
00, which may have relevance in developing regi-
ens for GVHD prophylaxis.
Many studies had previously shown a close rela-
ion between GVHD and GVT responses after my-
loablative HCT. GVT effects were investigated in
22 recipients of nonmyeloablative conditioning and
elated or unrelated donor grafts. Fifty-seven percent
f patients with measurable disease achieved a com-
lete (44%) or partial (13%) remission after HCT
14]. Grade II-IV aGVHD did not affect relapse/
rogression but was associated with increased NRM
nd poorer progression-free survival. Chronic GVHD
as associated with decreased relapse/progression
ith better progression-free survival without increase
n NRM. Currently, trials are ongoing to evaluate new
pproaches in GVHD prophylaxis to help improve
urvival.
onmyeloablative HCT after Failed
igh-dose HCT
Data were analyzed from 147 patients (median
ge, 46 yr) given an HLA-matched related (n  62) or
nrelated (n  85) hematopoietic cell tranplant after
ailing a myeloablative autologous (n  135), alloge-
eic (n  10), or syngeneic (n  2) HCT [18]. Three-
ear probabilities of NRM, progression-free, and
verall survivals were 32%, 20%, and 27% in related
nd 28%, 28%, and 44% in unrelated recipients, re-
pectively. Best outcomes were observed in patients
ith NHL, with 3-yr probabilities of progression-free
urvival of 57% and 56% in patients with mantle cell
ymphoma and indolent NHL, respectively, whereas
atients with Hodgkin lymphoma (HL) and multiple
yeloma (MM) had higher incidences of relapse/
rogression, resulting in poorer outcomes. cisease-specific Results
The following results in 3 different hematologic
alignancies are from multi-institutional studies us-
ng ﬂudarabine and 2-Gy TBI conditioning. Encour-
ging results were observed in 122 patients (related
onor, n  58; unrelated donor, n  64) with AML
19]. Cumulative NRMs were 10% and 22% for re-
ated and unrelated donor recipients at 2 yr, respec-
ively. The overall and progression-free 2-yr survivals
ere 48% and 44%, respectively. Patients undergoing
ransplantation in ﬁrst CR from unrelated donors had
igher 2-yr overall survival (63% versus 44%) and
ower risk of relapse (16% versus 50%) than did re-
ipients of related donor grafts, suggesting enhanced
VT effect mediated by unrelated donor cells.
Sixty-four patients with chemotherapy-refractory
LL were given HCT from HLA-matched related
n  44) or unrelated (n  20) donors after condi-
ioning with ﬂudarabine/2-Gy TBI [20]. Two-year
stimates of NRM, progression-free, and overall sur-
ivals were 22%, 52%, and 60%, respectively. Unre-
ated HCT resulted in higher CR and lower relapse
ates than did related HCT.
HLA-matched related (n 16) and unrelated (n
7) donor HCTs were carried out in patients with
elapsed or refractory mantle cell lymphoma including
4 patients whose previous autologous HCT had
ailed [21]. The 2-yr probabilities of NRM, progres-
ion-free, and overall survival were 24%, 60%, and
5%, respectively. Results suggest that mantle cell
ymphoma is responsive to GVT effects.
uture Directions
Nonmyeloablative conditioning using ﬂudara-
ine/2-Gy TBI provides a potentially curative option
or patients who were previously considered ineligible
or HCT. Patients have consistent engraftment and
vidence exists for GVT effects. We are currently
arrying out a prospective, phase III, randomized trial
valuating nonmyeloablative versus myeloablative
CT for patients with myelodysplastic syndrome
r AML in CR at the time of HCT. Other research
s directed at decreasing GVHD incidence and thus
inimizing the need for prolonged steroid use
which puts patients at risk for infectious complica-
ions) with subsequent reduction of NRM. To ex-
and the donor pool, ongoing trials are using HLA-
ismatched, including haploidentical, donors. For
atients with aggressive diseases, studies are investi-
ating the combination of nonmyeloablative condi-
ioning with “disease-targeted” therapy such as radio-
abeled mAbs, imatinib, or rituximab. Investigation
egarding tumor antigens and tissue-speciﬁc mHAs
ay allow administration of tumor-speciﬁc cytotoxic
cells to allow for more GVT effects without in-reasing the risk of GVHD.
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B. M. Sandmaier et al.90LEMTUZUMAB AND REDUCED INTENSITY
RANSPLANTATION FOR LYMPHOMA
he Antibody and Pharmacokinetics
Alemtuzumab (CAMPATH-1H) is a humanized
gG1 monoclonal antibody directed against the CD52
ntigen, which is widely expressed on all human lym-
hoid cells except terminally differentiated plasma
ells [22]. Delayed clearance of the mAb may impair
mmune reconstitution, affect rates of viral reactiva-
ion, and limit efﬁcacy of the donor T cell-mediated
VT effect derived from the graft itself, early adop-
ive immunotherapy, or later DLI. By administering
he Ab to the recipient as part of the conditioning
egimen, it will result in T cell, B cell, and selected
C depletion of the recipient [23]. Among myeloid
Cs, CD52 expression is limited to circulating and
onocyte-derived DCs [24]. Neither Langerhans
ells nor dermal-interstitial DCs express CD52,
hether resident in tissues or generated ex vivo with
ytokines [24]. In addition, if sufﬁcient Ab is circulat-
ng on the day of transplantation, this will result in
cell depletion of the graft, thereby potentially reduc-
ng the incidence and severity of GVHD. The half-life
f alemtuzumab in humans is dependent on the
mount of target CD52 antigen in the patient. After a
ose of 20 mg/d for 5 d (days8 to4) in vivo before
llogeneic HCT, there is persistence of alemtuzumab
n vivo past day 0 sufﬁcient to cause T cell lysis by
omplement ﬁxation and antibody dependent cell me-
iated cytotoxicity (ADCC) [25]. Using this dose
chedule, signiﬁcant levels of Ab persist through day
8 after transplantation. The optimal dose of antibody
o prevent GVHD and minimize post-transplantation
mmune suppression is currently unknown.
educed intensity Regimens Incorporating
lemtuzumab
The most commonly used regimen combines ale-
tuzumab with ﬂudarabine and an alkylating agent,
sually melphalan or busulfan [26,27]. Alemtuzumab
as also been added to the carmustine/etoposide/cyt-
rabine/melphalan (BEAM) regimen and used in re-
uced intensity conditioning for lymphoma [28]. These
egimens vary in their myeloablative and immunosup-
ressive properties, and it is currently not known
hich regimen is optimal for any given clinical sce-
ario.
oxicity
Reduced intensity conditioning regimens that in-
lude alemtuzumab have been generally well toler-
ted. Although many of the regimens containing mel-
halan or busulfan will result in 5-7 d of neutropenia,
voidance of methotrexate for GVHD prophylaxis
inimizes mucositis and allows most patients to con- ainue to eat relatively normally. However, there is
nfusional toxicity related to alemtuzumab. This is
econdary to a cytokine release syndrome that can
ause fever, skin rashes, hypotension, and occasionally
ronchospasm. This can be reduced by using a pre-
ed of methylprednisolone 2 mg/kg i.v. administered
efore the ﬁrst 20-mg dose of alemtuzumab. This is
ery effective at preventing the cytokine release. Oc-
asional patients may require corticosteroids after the
rst day of infusion.
ngraftment and Chimerism
The largest experience has used alemtuzumab in
ombination with ﬂudarabine and melphalan. Using
his regimen, the median time to recover an absolute
eutrophil count of 0.5 109/L was 13 d (8-23 d) and
count 1.0  109/L was 17 d (8-47 d). The median
ime to achieve a platelet count20 109/L was 13 d
range, 3-96 d) and a count 50  109/L was 17 d
8-118 d). Incidences of graft rejection were 3%
sing PBSCs from sibling donors and 6% with BM
rom unrelated donors [29]. Lineage-speciﬁc chimer-
sm studies have been performed using microsatellite
CR in patients after this regimen. Three patterns of
himerism have been documented using this regimen:
. Fully donor in all lineages
. Mixed chimera in all lineages
. Fully donor myeloid chimerism with mixed T cell
chimerism
Because reduced intensity transplantation is
eavily dependent on GVT effects, the development
f mixed T cell chimerism (a marker of bidirectional
mmune tolerance) could be associated with a higher
ncidence of disease relapse. Therefore, if mixed chi-
erism persists once immunosuppression has been
iscontinued, attempts to promote full donor chimer-
sm and graft-versus-leukemic activity using DLI
ight reduce disease recurrence. Most patients with
table mixed chimerism will achieve full donor chi-
erism after administration of DLIs (see below).
raft-versus-Host Disease
Perhaps the most impressive effect of alemtu-
umab as part of a reduced intensity conditioning
egimen is in the prevention of GVHD. Published
esults of sibling donor HCT using other nonmyeloa-
lative conditioning regimens have shown a 38%-
0% incidence of grade II-IV aGVHD that is the
rimary cause of death in some patients. However,
hen alemtuzumab has been used as part of the con-
itioning regimen using HLA-identical siblings, most
atients do not develop any GVHD, and the reported
ncidence of grade II-IV aGVHD after HLA-identical
ibling transplantation was 5% [26]. When transplants
sing unrelated donors are assessed, the effects of
lemtuzumab in not only preventing GVHD but also
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Reduced Intensity Allogeneic Transplantation 91imiting TRM are particularly impressive. For re-
uced intensity regimens that do not include alemtu-
umab, the reported experience of unrelated donor
CT using a ﬂudarabine-plus-melphalan protocol
bserved high rates of severe GVHD, with 1 in 4
atients dying directly as a result of GVHD. In con-
rast, a similar regimen containing alemtuzumab was
ssociated with a low incidence of GVHD despite
igniﬁcant HLA disparity in many transplants. Only
% of patients had grade III-IV aGVHD, and only
5% developed grade II aGVHD [29].
odgkin Lymphoma
The therapeutic options for patients with HL who
elapse soon after completion of ﬁrst-line chemother-
py or whose autologous transplant has failed are very
imited. The efﬁcacy of an allogeneic myeloablative
ransplant in HL remains controversial, and possible
eneﬁt was eliminated by very high NRM using TBI-
ased conditioning regimens. An alemtuzumab-based
educed intensity conditioning regimen has been re-
orted in 49 patients with HL [30]. Median age was 32
r; number of prior treatment lines was 5; and time
rom diagnosis was 4.8 yr. Forty-four patients had
ndergone prior autologous transplantation. Thirty-
ne had HLA-matched related and 18 HLA-unrelated
onors. Median follow-up was 967 d. Grade II-IV
GVHD occurred in 12% before DLI and cGVHD in
6%. Sixteen received DLI beginning 3 mo after
ransplantation for residual disease/progression. Six
eveloped grade II-IV aGVHD and 5 developed
GVHD. Nine demonstrated disease responses after
LI (7 complete, 2 partial). NRM was 15% with an
dditional 9% mortality associated with DLI (overall
rocedural mortality, 24%; 17% related versus 39%
nrelated donors; P  .06). Projected 4-yr overall and
urrent progression-free survivals were 59% and 39%,
espectively (66% and 41% for related donors). These
ata strongly support a clinically relevant graft-ver-
us-HL effect and demonstrate the potential for du-
able responses even in this group of heavily pre-
reated HL patients. The relatively low procedural
ortality allows consideration of application sooner in
he disease course, particularly in the related donor
ohort, and support further exploration of allogeneic
herapies.
on-Hodgkin Lymphoma
Results in 121 patients with NHL/CLL who un-
erwent transplantation using an alemtuzumab, ﬂu-
arabine, and melphalan regimen were recently re-
orted [31]. Diagnoses were in 3 categories: low-grade
ollicular NHL (n  50), mantle cell lymphoma (n 
1), and high-grade NHL (n  50, including trans-
ormed low-grade disease in 15). Donors were HLA-
atched siblings in 75 (62%) and unrelated in 46 l38%), 18 of whom were HLA-mismatched at up to
/10 loci. Forty-eight percent of patients had failed
revious autologous HCT. Median follow-up was 35
o (1-78 mo). For the group with low-grade follicular
HL (n  50), estimated overall survivals were 76%
t 1 yr and 67% at 4 yr, and NRM was 15% at 4 yr.
isease relapse or progression occurred in 12 patients,
f whom 8 received DLI, with responses in 6. Current
rogression-free survival is 69% at 4 yr (Figure 1A).
or the group with mantle cell lymphoma (n  21),
stimated overall survival was 83% at 4 yr, NRM was
1% at 4 yr, and relapse or progression occurred in 6
atients. Three patients received DLI, with nonsus-
ained responses in 2. Current progression-free sur-
ival is 43% at 4 yr. For high-grade NHL (n  50),
stimated overall survivals were 52% at 1 yr and 45%
t 4 yr. Prior autologous HCT was common in this
roup (72%), and NRM was higher at 34% at 1 yr and
7% at 4 yr. Progression/relapse occurred in 15 pa-
ients, of whom 10 received DLIs, with responses in 5.
urrent progression-free survivals are 48% at 1 yr and
8% at 4 yr (Figure 1B).
igure 1. NRM and current progression-free survival for (A) fol-
icular lymphoma and (B) aggressive lymphoma.
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B. M. Sandmaier et al.92onor Lymphocyte Infusion
After reduced intensity conditioning, the pres-
nce of mixed chimerism or residual tumor are risk
actors for disease recurrence. DLI can promote full
onor chimerism and graft-versus-leukemic effects
ut are associated with a high risk of GVHD early
fter transplantation. Although DLI with a T cell
ontent of 1  107/kg is relatively safe if adminis-
ered 1 yr after transplantation [32], there are few
ata on the effective and safe dose of DLIs that can
e given early after transplantation. A trial of DLI
fter a reduced intensity alemtuzumab-containing
egimen has been reported [33]. The number of
atients with NHL given this treatment has in-
reased since the time of that publication. Sixty-
ight infusions of dose-escalating DLI have been
dministered to 28 allogeneic transplant recipients.
he diagnoses were indolent NHL (n  23) and
ransformed NHL (n  5). Indications for DLI
ere progressive disease with/without mixed chi-
erism (n  17) or persistent mixed chimerism
lone (n  11). Escalating doses of cells were ad-
inistered in the absence of GVHD for persistent
ixed chimerism or until disease response. Thir-
een of 16 evaluable patients (81%) treated for dis-
ase progression showed a signiﬁcant response to
LI, and all 23 evaluable patients treated for mixed
himerism converted to stable donor hematopoiesis
100%). The major toxicity resulting from the use
f DLI was GVHD. The cumulative incidence of
rade II-IV aGVHD was 15%, and that of extensive
GVHD was 35%; there were no deaths due to
VHD. Seven patients had graft-versus-lymphoma
esponses without signiﬁcant GVHD. These data
upport the existence of a clinically signiﬁcant GVT
ffect in NHL and indicate that this is an effective
reatment for progressive disease after allogeneic
CT.
ummary
Alemtuzumab reduces the incidence of aGVHD
nd cGVHD after reduced intensity conditioning
CT and reduces GVHD-related mortality. There is
delay in immune reconstitution and an increased
ncidence of viral infections with the use of alemtu-
umab; however, in the case of CMV, this does not
dversely affect TRM. Many patients develop mixed
himerism with this approach and full donor chimer-
sm can usually be achieved after DLI. In patients with
ndolent lymphoma and HL, these DLIs are asso-
iated with impressive graft-versus-lymphoma re-
ponses. The optimal dose of alemtuzumab remains
nknown. Whether this antibody will improve
ong-term progression-free survival compared with
ther reduced intensity conditioning regimens us- ang conventional GVHD prophylaxis also remains
nknown.
LLOGENEIC TRANSPLANTATION FOR
ONHEMATOLOGIC CANCERS
Allogeneic T cells are capable of generating anti-
eukemic effects in a number of hematologic malig-
ancies after HCT. This GVT effect is powerful
nough to cure patients with hematologic cancers who
ave become completely resistant to chemotherapy.
ver the past 20 yr, the list of malignant diseases
hown to be susceptible to the GVT effect has grown
o include acute and chronic leukemias, post-trans-
lantation EBV-associated lymphoproliferative disor-
er, HL, NHL, and MM.
The failure of conventional chemotherapy to
mprove survival in many metastatic cancers has
rovided an impetus for the development of im-
une-based treatment approaches for solid tumors.
nitial efforts were directed at nonspeciﬁc enhance-
ent of innate immunity through the administra-
ion of immunomodulatory cytokines. Unfortu-
ately, cytokine-based immunotherapy has proved
o be inactive in most solid tumors. Perhaps the
reatest limitation of conventional immunotherapy
egimens is that they attempt to enhance a host
mmune system rendered dysfunctional by prior
hemotherapy treatment or longstanding exposure
o the immunosuppressive effects of the tumor. Al-
ogeneic HCT, a procedure that culminates in com-
lete immune replacement, could potentially over-
ome this problem and at the same time expand the
epertoire of immune cells capable of recognizing
umor antigens, including tumor-reactive T cells
hat recognize polymorphic variants of mHAs. The
ntroduction of reduced intensity conditioning reg-
mens that have decreased TRM and preserved
VT effects has recently led investigators to ex-
lore the potential of allogeneic immunotherapy to
reat incurable metastatic cancers [34,35].
Since 1999, there have been a number of publica-
ions describing GVT effects in patients with a variety
f solid tumors undergoing reduced intensity HCT
36,37]. At present, 12 case series describing the re-
ults of nonmyeloablative HCT for renal cell carci-
oma (RCC) and 5 small series of HCT in breast
ancer have been reported. Although partial responses
ave most often been observed in patients having
vidence for a GVT effect, a subset of patients had
ramatic complete responses that have proved to be
urable. Numerous case reports and a few case series
eporting evidence for GVT effects in other solid
umors including metastatic pancreatic carcinoma, co-
on carcinoma, ovarian carcinoma, and sarcomas have
lso been reported over the past 2 yr [34]. In several
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Reduced Intensity Allogeneic Transplantation 93eries, survival has been reported to be signiﬁcantly
uperior in patients having a GVT effect compared
ith nonresponders [38-40].
llogeneic HCT for Metastatic RCC
Since 1998, we and others have conducted pilot
rials investigating for GVT effects after nonmyeloa-
lative allogeneic HCT in patients with metastatic
CC. Twelve studies evaluating a variety of nonmy-
loablative allogeneic transplantation approaches for
etastatic RCC have thus far been reported (Table 1)
38-50]. In 9 of these series, disease regression com-
atible with a GVT effect has been observed to occur
n a subset of patients. Although most of these series
ave been small, they have demonstrated the feasibil-
ty of nonmyeloablative HCT for metastatic RCC and
llustrated the following principles:
Conversion from mixed to full donor chimerism
can be accelerated by withdrawal of immunosup-
pression and/or DLI and is important to enhance
a GVT effect.
Acute GVHD correlates with donor immune-
mediated tumor responses.
RCC resistant to cytokine therapy, including
IFN- and high-dose IL-2, may respond after
nonmyeloablative HCT.
Development of a GVT effect is delayed after
HCT, underscoring the importance of careful
selection of patients with sufﬁcient pretransplan-
tation life expectancy.
Response rates have been extremely variable, with
a range of 8%-57%. The familiarity of trans-
plantation centers with this approach and pro-
tocol-speciﬁc selection criteria used to deter-
mine patient eligibility have contributed to this
variability.
The largest experience to date of allogeneic HCT
or metastatic RCC was recently reported from a
ooled series of 21 different European transplantation
able 1. Published Series of Nonmyeloablative HCT to Treat Metastat
Study n Conditioning
hilds et al [37] 19 Flu  Cy
ini et al [41], Artz et al [50] 18 Flu  Cy
regni et al [42] 7 Flu  TT
edrazzoli et al [43] 7 Flu  Cy
laise et al [44] 25 Flu  Bu  ATG
akagawa et al [46] 9 Flu/Cla  Bu  ATG
eno et al [40] 15 Flu  Mel
entschke et al [47] 10 Flu  TBI  ATG
assenkeil et al [48] 7 Flu  Cy  ATG
ykodi et al [45] 8 Flu  TBI
ini et al [49] 22 Flu  Cy
arkholt et al [38] 124 Multiple variables
u indicates busulfan; Cla, cladribine; Cy, cyclophosphamide; Flu
TT, thiotepa.Mixed responses observed.enters [38]. One hundred twenty-four patients un-
erwent transplantation using a variety of different
ransplantation regimens. A tumor response was ob-
erved in 28 of 98 evaluable patients (cumulative in-
idence, 32%), including 24 partial responses and 4
omplete responses. In a multivariate analysis, tumor
esponses were associated with aGVHD, use of an
LA-mismatched donor, and a period 1 yr from
iagnosis of metastatic disease to transplantation. In a
ultivariate analysis of overall survival, the presence
f cGVHD, DLI after transplantation, and having 3
etastatic sites were associated with improved survival
fter HCT.
Experience in humans has shown that allogeneic
VT effects are most effective when performed dur-
ng a state of minimal residual disease. The intrinsic
elay to tumor regression makes careful selection of
atients for the procedure obligatory. A recent report
as shown that performance status, C-reactive protein
evels, and lactate dehydrogenase levels could be used
n a Cox regression model to predict survival after
llogeneic HCT, potentially providing a tool to assist
linicians in selecting patients who would be appro-
riate candidates for this approach [51].
The identiﬁcation of mechanisms through which
raft-versus-RCC effects occur and the antigens ex-
ressed on RCC cells that serve as targets for donor
mmune cells remain active areas of investigation
52,53]. Recently, T cells with in vitro tumor cyto-
oxicity patterns consistent with recognition of
HAs and tumor-restricted antigens have been
dentiﬁed in some responding patients [45,54]. The
dentiﬁcation of tumor-restricted antigens targeted
y donor immune cells could lead to the develop-
ent of transplantation approaches that enhance
VT effects and avoid GVHD by incorporating
trategies such as tumor vaccination or the adoptive
nfusion of in vitro expanded donor T cells with
umor-antigen speciﬁcity.
aGVHD, % cGVHD, % TRM, % Response Rate, %
53 21 11 53
22 39 14 22
86 71 0 57
0 N/A 29 0
42 60 9 8
44 44 0 11
47 27 33 20
50 30 40 0*
29 57 14 29
50 50 13 13
50 23 9 0
40 33 16 32
rabine; Mel, melphalan; N/A, not available; TBI, 200-cGy TBI;ic RCC
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B. M. Sandmaier et al.94We have successfully generated donor CD8 T
ell clones from lymphocytes obtained from respond-
ng patients that have direct cytotoxicity against the
atient’s RCC cells. Using cDNA expression cloning,
e recently identiﬁed a tumor antigen recognized by
n HLA-A 11 restricted RCC-speciﬁc T cell clone
solated from a patient at the time of tumor regression
donor in origin). Importantly, this antigen was found
o be derived from a newly discovered gene expressed
n 50% of RCC lines but not in any normal tissues
Takahashi Y, Harashima N. et al, 2006, unpublished
bservations).
llogeneic HCT for Breast Cancer
Recent reports of GVT effects occurring in
omen with metastatic breast cancer after reduced
ntensity conditioning regimens have provided a re-
ewed impetus to study HCT as immunotherapy for
his disease (Table 2) [40,42,44,55,56]. As observed in
atients with RCC having a GVT effect, tumor re-
ression has most often been described to occur after
ull donor chimerism is achieved, often in association
ith GVHD or after DLI.
An innovative approach using tandem autologous
ollowed by allogeneic HCT for patients with heavily
retreated metastatic breast cancer was recently re-
orted by investigators from Italy [56]; in 3 of 17
atients, durable complete responses ongoing 1320,
530, and 2160 d after HCT were observed. Together
hese results establish the existence of GVT effects
gainst metastatic carcinoma of the breast, which in
elect patients may lead to considerable DFS. Further
rospective studies are clearly warranted to better
valuate the potential of allogeneic HCT for this solid
umor type.
uture Directions
Nonmyeloablative transplantation trials showing
VT effects in metastatic solid tumors provide fur-
her proof of the strength of allogeneic immunother-
py. Trials evaluating nonmyeloablative approaches
sing unrelated donors for patients with metastatic
CC have recently been initiated and, if effective,
ould potentially expand the application of allogeneic
mmunotherapy to a far larger number of patients.
owever, the use of allogeneic HCT to treat solid
able 2. Published Series of Nonmyeloablative HCT to Treat Metastat
Study n Conditioning aGV
eno et al [40] 8 Flu  Mel 2
regni et al [42] 6 Flu  TT 2
laise et al [44] 12 Flu  Bu  ATG 5
ishop et al [55] 16 Flu  Cy 9
arella et al [56] 17 Flu  Cy 5u indicates busulfan; Cy, cyclophosphamide; Flu, ﬂudarabine; Mel, melpumors will likely remain limited until the safety and
fﬁcacy of the approach are improved. Concerns over
ransplant-associated complications continue to make
eferring oncologists reluctant to send patients for
hese investigational studies. As a consequence, the
pproach is further limited by its obligate enrollment
f patients with advanced, treatment refractory dis-
ase, often with life expectancies too short to beneﬁt
rom a delayed GVT effect [36]. Further progress in
he ﬁeld will require the development of strategies
hat limit GVHD and target the allogeneic T cells to
he tumor. The development of novel regimens that
ncorporate maneuvers to control or shrink the tumor
o buy time for a GVT effect to occur could also be
sed to improve transplantation outcome. The feasi-
ility of incorporating receptor tyrosine kinase inhib-
tors including sunitinib and sorafenib and the vascu-
ar endothelial growth factor antibody bevacizumab
fter allogeneic HCT for RCC is currently being
valuated at the National Heart, Lung, and Blood
nstitute. Another strategy to enhance GVT effects
gainst RCC is the use of alloreactive KIR-incompat-
ble NK cells in the transplantation regimen. In vitro,
llogeneic KIR-incompatible NK cells have enhanced
ytotoxicity against RCC cells compared with autolo-
ous or KIR-matched NK cells [57]. Adoptive infu-
ion of alloreactive donor NK cells was recently found
o signiﬁcantly reduce the risk of aGVHD and poten-
iate graft-versus-RCC effects in a murine model of
CT for kidney cancer (Ludqvist A, et al, unpub-
ished observations). Trials evaluating adoptively in-
used allogeneic NK cells and other novel methods to
irect/target alloimmune cells against the cancer in
umans undergoing HCT for metastatic RCC will
ikely be explored in the near future.
ONCLUSIONS
Results of reduced intensity and nonmyeloablative
CT studies over the past decade are encouraging,
nd the knowledge gained thus far is instrumental in
he design of clinical trials. Less toxic regimens can be
mplemented and preserve potent GVT effects in he-
atologic and nonhematologic malignancies. Current
hallenges include optimizing the regimen to still al-
ow for a GVT effect while minimizing toxicities,
t Cancer
) cGVHD (%) NRM, % Response Rate (%)
6 (75) 0 2 CR (25)
2 (33) 0 2 PR (33)
7 (60) 9 1 CR, 1 PR (17)
4 (25) 13 2 PR (13)
6 (35) 24 3 CR, 1 PR (24)ic Breas
HD (%
(25)
(33)
(42)
(56)
(29)halan; PR, partial remission; TT, thiotepa.
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Reduced Intensity Allogeneic Transplantation 95ncluding serious GVHD and infections. Further
rogress in adoptive transfer of T or NK cell popula-
ions with relative tumor speciﬁcity in combination
ith disease-targeted therapy would make reduced
ntensity HCT even more effective. Prospective dis-
ase-speciﬁc randomized trials evaluating reduced in-
ensity or nonmyeloablative regimens versus myeloa-
lative regimens in younger patients are needed to
eﬁne the role in this population for reduced intensity
CT.
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